当前位置: 首页 > 详情页

Plasma fibroblast growth factor 23 is elevated in pediatric primary hypertension

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Pediatric Cardiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China, [2]Central Diagnostic Laboratory, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China, [3]Department of Epidemiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China
出处:
ISSN:

关键词: Blood pressure Cardiovascular disease FGF 23 Left ventricular hypertrophy Pediatric primary hypertension

摘要:
Fibroblast growth factor 23 (FGF 23), an endocrine hormone regulating the homeostasis of phosphate and vitamin D, has been shown to play a role in cardiovascular disease. Increased blood FGF 23 is found to be associated with elevated blood pressure in adults. However, measurement of FGF 23 in hypertensive children has not been documented. In this study, a total of 98 children with primary hypertension and 37 controls were recruited, and blood FGF 23 was comparatively investigated. Additionally, FGF 23 levels were compared between the subgroups of patients after hypertensive children were sub-grouped according to their cardiac geometry, hypertension stages, insulin levels, and weight. The case group had a FGF 23 level of 48.99 (16.42), expressed as the median (the interquartile range), significantly higher than the 41.72 (7.05) from the control group (p = 0.0002). While no remarkable differences were observed in FGF 23 levels between non-obese and obese hypertensive children, between patients with stage 1 and stage 2 hypertension, or between patients with normal and high insulin levels; hypertensive children with abnormal cardiac geometry had significantly higher levels of FGF 23 than patients with normal cardiac geometry (p = 0.0085). Our data revealed for the first time that hypertensive children have higher levels of FGF 23. Further studies are needed to examine if lowering FGF 23 improves the cardiac geometry in hypertensive children with higher FGF 23. © 2019 Lin, Shi, Liu, Zhang, Liu, Huang, Hou and Zhang.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 儿科
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 儿科
JCR分区:
出版当年[2017]版:
Q2 PEDIATRICS
最新[2023]版:
Q2 PEDIATRICS

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Pediatric Cardiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China,
通讯作者:
通讯机构: [1]Department of Pediatric Cardiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China,
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17069 今日访问量:0 总访问量:916 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院